Two billion! Well-known Chinese medicine enterprises treasure island to make chemical drugs.

Pharmaceutical Network August 17 - Treasure Island, a well-known Chinese medicine company, said it will raise no more than 2.08 billion yuan for innovative drugs and generic drug research and development platforms and other projects.
August 12, Treasure Island Pharmaceuticals announced that the total amount of funds to be raised from the proposed non-public offering of shares will not exceed 208,109.05 million yuan - the net amount of funds raised will be used for innovative pharmaceutical and generic drug research and development platform projects, the third phase of the Chixi Branch project construction projects, chinese herbal medicine processing projects, information upgrading construction projects and supplementary liquidity.
, the company is expected to invest 1.3 billion yuan in innovative drug and generic drug research and development platform projects.
according to Treasure Island Pharmaceuticals' 2019 results, in 2019, while continuing to focus on promoting the research and development of Chinese medicines, it will also vigorously promote the process of generic drugs, innovative drug research, production and marketing.
in particular, it has strengthened research and development of chemical drugs for the domestic market- including 3 innovative drugs in research and development, 42 generic drugs and 2 consistency evaluation projects.
previous public information, Treasure Island Pharmaceuticals has said that its research and development work is gradually from traditional Chinese medicine to the field of chemical and biological medicine.
Treasure Island Pharmaceuticals' 2019 annual report shows that last year, it achieved operating income of 3.292 billion yuan, up 18.37 percent year-on-year, and net profit attributable to shareholders of listed companies was 409 million yuan, down 11.63 percent year-on-year.
, commercial and medicinal sales revenue increased by 75.1% compared to 2018, while operating costs also increased by 86.62% compared to 2018.
's operating income from biologics decreased by 35.09 percent compared to 2018, mainly due to the inclusion of injectable bone peptides in the First National List of Key Monitoring Rational Drugs, and the monitoring of clinical use of pharmaceuticals by medical institutions, resulting in a decrease in sales of bone peptides for injection.
Chemical products operating income increased by 32.83 percent compared to 2018, mainly due to the flu outbreak in early 2019, the increased market demand for injectable inflammatory amber products: and Treasure Island upgraded the product, in 2018 adopted and implemented the country's new quality standards, product quality is more stable, more accurate efficacy, resulting in higher sales.
In its 2019 Annual Report, Treasure Island said that in view of the current market pattern of large-class drugs in the pharmaceutical market, it has adjusted the direction of new product research and development, increased research and development of drugs in the cardiovascular system, skeletal muscle system, neuropsychia, anti-tumor, anti-infection, digestive metabolism, respiratory system, etc., to enhance the research of technical barriers such as slow-control release agents, to carry out generic quality and consistent evaluation of efficacy, and to enrich product lines and enhance the company's long-term competitiveness.
Treasure Island said that its plan to scientifically lay out the pipeline of Chinese medicine, chemical and biological drug products, and make extensive use of all resources, in the full accumulation of research and development experience, looking for research and development breakthrough on the basis of the gradual involvement in high-end preparations, innovative drug research and development.
previously, treasure island in order to enter the field of biomedicine, but also as a limited partner to participate in the establishment of Harbin Jinzhen Biopharmaceutical Investment Center (limited partnership), the contribution of 345 million yuan, the partnership share of 69%.
part of the Chinese medicine business, there is a downward trend Although the new crown epidemic promoted the sales of some Chinese medicine products, but in the focus on monitoring the drug system and health insurance catalog dynamic adjustment and use restrictions under the influence of many Chinese medicine enterprises are also facing pressure, Treasure Island is no exception.
said that the introduction of the national focus on monitoring the introduction of a list of rational drugs and the publication of local key monitoring drug catalogues limited the clinical use of some of its products.
July 1, 2019, the State Health And Health Commission issued the first batch of national key monitoring of rational drug drug catalog, to strengthen the rational drug management, and to develop provincial and medical institutions directory, the catalog of drugs key monitoring, out-of-catalog drugs to strengthen prescription management.
for injection of bone peptides into the first batch of national key monitoring of rational drug catalogues (chemicals and biological products).
In addition, on August 20, 2019, the State Health Insurance Administration issued a new edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog, which will focus on monitoring the transfer of all drugs, and set a time limit for digestion of Class B drugs that have been added in the original provincial drug catalogue in accordance with the provisions.
the limited medical insurance for injection of blood plugs (freeze-dried), Shu henning injections and injections of bone peptides, there was a downward trend in sales in the fields of cardiovascular medicine for traditional Chinese medicine and skeletal system for chemical drugs.
In addition, due to the national price linkage, Shu Blooding injection winning price fell, market competitiveness decreased, resulting in a decline in sales volume;
In addition, the decline in the number of medical institutions below level 2 for injection of blood plugs (freeze-dried) was also very significant, with a decrease of 3.26 percentage points, a decrease of 3.26 percentage points in each medical terminal of Shu Bloodin injection, a decrease of 1.3 percentage points in the total amount of injection bone peptides in each medical terminal, and a decrease of 5.2 percentage points in the total.
said in its 2019 annual report that in response to the decline in product sales, it had adopted a production model based on sales of injectables, which reduced production to avoid product backlogs and reduce production, while reducing inventory of finished products on the basis of ensuring market availability.
In addition, it also improves guidelines and norms for the use of bone peptides for injection in accordance with policy requirements, clarifies the conditions and principles of clinical application, and guarantees clinical rational use of drugs;
and simultaneously carry out market research, analysis of product growth potential and space, focusing on orthopaedic hospitals and work injury fixed-point hospitals, secondary and third-level hospitals, to carry out a reasonable layout of the terminal.
During the reporting period, Treasure Island, in order to resist the impact of the decline in sales of Chinese medicine injections, began to add code oral preparations layout - put forward "injections and oral preparations of the two-line development strategy", speed up the development of oral preparations, high-volume work, while increasing the promotion of oral preparations, to carry out oral preparations as the core of professional academic conferences, end-point consultation, patient services and other activities.
said oral products had achieved good growth in 2019, laying a good sales forecast for 2020.
In last year's financial results, Treasure Island stressed that it will further highlight scientific and technological innovation, focus on increasing research on exclusive product acquisitions and acquisitions of Chinese medicine, and actively build product pipelines and product structures based on Chinese medicine products, supported by chemical products, transformed by bio-innovative drugs, with core market competitiveness.
In the background of chinese medicine pressure, plus code biological medicine, chemical medicine is the choice of many Chinese medicine enterprises, but it is worth noting that in the field of biological medicine, chemical medicine, but also face the risk of research and development investment, including the purchase of band volume, drug prices down and other pressures.
.